Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
53
PETS Quote, Financials, Valuation and Earnings
Last price:
$3.58
Seasonality move
:
5.08%
Day range:
$3.40 - $3.64
52-week range:
$1.57 - $5.58
Dividend yield:
0%
P/E ratio:
337.00x
P/S ratio:
0.38x
P/B ratio:
1.76x
Volume:
266.8K
Avg. volume:
5.2M
1-year change:
-29.98%
Market cap:
$75.9M
Revenue:
$227M
EPS (TTM):
-$2.65
Analysts' Opinion
-
Consensus RatingPetMed Express, Inc. has received a consensus rating of Sell. The company's average rating is a Sell based on 0 Buy ratings, 0 Hold ratings, and 1 Sell rating.
-
Price Target DownsideAccording to analysts' consensus price target of $2.75, PetMed Express, Inc. has an estimated downside of -22.54% from its current price of $3.55.
-
Price Target UpsideAccording to analysts, the highest upside price target is $2.75 representing -100% upside increase from its current price of $3.55.
Fair Value
-
According to the consensus of 1 analyst, PetMed Express, Inc. has -22.54% downside to fair value with a price target of $2.75 per share.
PETS vs. S&P 500
-
Over the past 5 trading days, PetMed Express, Inc. has underperformed the S&P 500 by -5.4% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
PetMed Express, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PetMed Express, Inc. revenues have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter PetMed Express, Inc. reported revenues of $44.4M.
Earnings Growth
-
PetMed Express, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter PetMed Express, Inc. reported earnings per share of -$0.41.
Enterprise value:
40.5M
EV / Invested capital:
0.92x
Price / LTM sales:
0.38x
EV / EBIT:
18.44x
EV / Revenue:
0.21x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-2.59x
Price / Operating cash flow:
62.27x
Enterprise value / EBITDA:
2.67x
Gross Profit (TTM):
$52.5M
Return On Assets:
-42.35%
Net Income Margin (TTM):
-28.22%
Return On Equity:
-73.88%
Return On Invested Capital:
-72.91%
Operating Margin:
-18.89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $270.5M | $256.1M | $195M | $58M | $44.4M | |
| Gross Profit | $70.4M | $66.8M | $52.5M | $17.1M | $10.1M | |
| Operating Income | -$1.7M | -$1.1M | -$19M | $554K | -$8.4M | |
| EBITDA | $3.6M | $6M | -$10.8M | $2.2M | -$6.1M | |
| Diluted EPS | -$0.03 | -$0.05 | -$2.65 | $0.11 | -$0.41 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $133.4M | $138.2M | $84.6M | $70.8M | $59.5M | |
| Total Assets | $159.4M | $169.3M | $162.7M | $146M | $100.3M | |
| Current Liabilities | $16.3M | $30.6M | $61.2M | $48.8M | $56.7M | |
| Total Liabilities | $17.9M | $31.1M | $62.3M | $49.6M | $57.2M | |
| Total Equity | $141.5M | $138.2M | $100.4M | $96.4M | $43.1M | |
| Total Debt | -- | -- | $1.1M | $768K | $291K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $22.5M | $3.4M | -$8.6M | $7.4M | -$2.2M | |
| Cash From Investing | -$40.9M | -$4.6M | -$7.1M | -$1.3M | -$2.6M | |
| Cash From Financing | -$24.6M | -$208K | -$267K | -$71K | -$231K | |
| Free Cash Flow | $17.4M | -$918K | -$15.7M | $6.1M | -$4.8M | |
PETS
Sector
Market Cap
$75.9M
$322.8M
Price % of 52-Week High
63.62%
73.39%
Dividend Yield
0%
0%
Shareholder Yield
0.21%
1.99%
1-Year Price Total Return
-29.98%
-3.6%
Beta (5-Year)
0.754
0.537
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
54.34%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.52
200-day SMA
Buy
Level
$3.12
Bollinger Bands (100)
Buy
Level
2.12 - 3.18
Chaikin Money Flow
Sell
Level
-1M
20-day SMA
Buy
Level
$2.56
Relative Strength Index (RSI14)
Buy
Level
68.63
ADX Line
Sell
Level
9.89
Williams %R
Neutral
Level
-21.7391
50-day SMA
Buy
Level
$2.44
MACD (12, 26)
Buy
Level
0.93
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Sell
Level
-2.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.1303)
Buy
CA Score
(Annual)
Level (0.4072)
Buy
Beneish M-Score
(Annual)
Level (-3.1299)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.9079)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PetMed Express, Inc. markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. The firm provides treatments for allergies, arthritis, anxiety, dermatitis, diabetes, and heartworms. It offers access to a range of non-prescription health and wellness products and Rx food, non-Rx food, and treats. The company was founded in January 1996 and is headquartered in Delray Beach, FL.
Stock Forecast FAQ
In the current month, PETS has received 0 Buy ratings 0 Hold ratings, and 1 Sell ratings. The PETS average analyst price target in the past 3 months is $2.75.
-
Where Will PetMed Express, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that PetMed Express, Inc. share price will drop to $2.75 per share over the next 12 months.
-
What Do Analysts Say About PetMed Express, Inc.?
Analysts are divided on their view about PetMed Express, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that PetMed Express, Inc. is a Buy and believe this share price will rise from its current level to $2.75.
-
What Is PetMed Express, Inc.'s Price Target?
The price target for PetMed Express, Inc. over the next 1-year time period is forecast to be $2.75 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PETS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PetMed Express, Inc. is a Sell. 1 of 1 analysts rates the stock a Sell at this time.
-
How Can I Buy Shares Of PETS?
You can purchase shares of PetMed Express, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PetMed Express, Inc. shares.
-
What Is The PetMed Express, Inc. Share Price Today?
PetMed Express, Inc. was last trading at $3.58 per share. This represents the most recent stock quote for PetMed Express, Inc.. Yesterday, PetMed Express, Inc. closed at $3.55 per share.
-
How To Buy PetMed Express, Inc. Stock Online?
In order to purchase PetMed Express, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PETS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PETS
Sector
P/E ratio
337.00x
17.48x
PEG ratio
0.00x
0.11x
P/B ratio
1.76x
1.33x
Price / LTM sales
0.38x
0.58x
Growth Metrics
PETS
Sector
Revenue growth
-23.57%
3.54%
Earnings growth
-467.15%
--
Revenue (5-year growth)
-4.39%
3.17%
Earnings forecast
--
$0.25
Profitability
PETS
Sector
Profitability FY 2024
$62.1M
$299.9M
Return on invested capital
-72.91%
3.41%
Return on assets
-42.35%
2.26%
Return on equity
-73.88%
5.88%
Earnings Date
Last Earnings Date
Aug
11
Next Earnings Date
Dec
25
Estimated Next Earnings Date
Mar
26
Balance Sheet
PETS
Sector
Total cash
$36.1M
$130M
Short term investments
--
$40.6M
Total assets
$148.7M
$1.1B
Long term debt
$291K
$35.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
